Histogenics Corporation Announces First Quarter 2015

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Histogenics Corporation Announces First Quarter 2015 Financial Results

WALTHAM, Mass., May 14, 2015 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX ), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced its financial and operational results for the first quarter ended March 31, 2015.  

"We continued to make progress toward our goal of enrolling our Phase 3 study of NeoCart ® by the second quarter of 2016.  Since we completed our initial public offering in late 2014, our team has continued enhancing and executing on our clinical enrollment plans and continued scaling and technology transfer activities in our manufacturing processes," stated Adam Gridley, President and Chief Executive Officer of Histogenics. "We implemented our recently approved health economics protocol amendments to capture additional patient outcomes to support our reimbursement strategy.  In parallel, our pipeline activities include continued progress in our collaboration with Intrexon Corporation, and the establishment of our recently established scientific advisory board."

Financial Results for the First Quarter 2015

For the first quarter of 2015, Histogenics reported a net loss of $(8.0) million, or $(0.60) per share, compared to a net loss of $(3.4) million, or $(5.90) per share for the same period in 2014, which included a $1.7 million gain related to fair value adjustments to certain liabilities that were either settled or terminated upon the closing of Histogenics' recent initial public offering (IPO). General and administrative expenses were $2.1 million in the first quarter of 2015, compared to $1.8 million in the first quarter of 2014.  The increase in general and administrative expenses was primarily the result of additional headcount and professional services. Research and development expenses were $5.8 million in the first quarter of 2015, compared to $3.4 million in the first quarter of 2014. The increase in research and development expenses in the first quarter of 2015 was primarily from the costs of enrollment of patients in Histogenics' NeoCart ® Phase 3 clinical trial, the agreement with Intrexon Corporation and its manufacturing scaling projects.

In January 2015, Histogenics raised an additional $5.1 million in gross proceeds related to the underwriter's overallotment exercise of its December 2014 IPO. With the inclusion of the underwriter's overallotment exercise, Histogenics raised approximately $70.1 million in gross proceeds, for a total of approximately $61.3 million in net proceeds.

At March 31, 2015 Histogenics had cash, cash equivalents and marketable securities of $53.2 million, compared to $58.1 million at December 31, 2014. Histogenics believes its current cash position will fund its operations into 2017.

Conference Call Information

Management will host a conference call on Thursday, May 14, 2015 at 8:30 a.m. EDT. A question-and-answer session will follow Histogenics' remarks. To participate on the live call, please dial (855) 890-8663 (domestic) or (720) 634-2936 (international) and provide the conference ID 39429810 five to ten minutes before the start of the call.

A live audio webcast of the presentation will be available via the "Investor Relations" page of the Histogenics website, www.histogenics.com . A replay of the webcast will be archived on Histogenics' website for approximately 30 days following the presentation.

About Histogenics Corporation

Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. Histogenics' regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. Histogenics' first investigational product candidate, NeoCart®, leverages its platform to provide an innovative treatment in the orthopedic space, specifically cartilage damage in the knee.

Forward - Looking Statements

Various statements in this release, including, but not limited to, the guidance provided under "2015 Financial Guidance" above, are "forward-looking statements" under the securities laws. Words such as, but not limited to, "anticipate," "believe," "can," "could," "expect," "estimate," "design," "goal," "intend," "may," "might," "objective," "plan," "predict," "project," "target," "likely," "should," "will," and "would," or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties.

Important factors that could cause actual results to differ materially from those reflected in the Company's forward-looking statements include, among others: the timing and success of Histogenics' NeoCart ® Phase 3 clinical trial, including, without limitation, possible delays in enrolling the NeoCart® Phase 3 clinical trial; the ability to obtain and maintain regulatory approval of NeoCart ® or any product candidates, and the labeling for any approved products; the scope, progress, expansion, and costs of developing and commercializing Histogenics' product candidates; the ability to obtain and maintain regulatory approval regarding the comparability of critical NeoCart ® raw materials following our technology transfer and manufacturing location transition; the size and growth of the potential markets for Histogenics' product candidates and the ability to serve those markets; Histogenics' expectations regarding its expenses and revenue; the sufficiency of Histogenics' cash resources and needs for additional financing; Histogenics' ability to attract or retain key personnel; the technologies on which Histogenics' channel partnering agreement with Intrexon Corporation is based are currently in preclinical and clinical stages of development; Histogenics will incur additional expenses in connection with its exclusive channel collaboration agreement with Intrexon Corporation and other factors that are described in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Histogenics' Annual Report on Form 10-K for the year ended December 31, 2014 filed with the SEC on March 27, 2015 and Quarterly Report on Form 10-Q for the three months ended March 31, 2015 to be filed with the SEC and available on the SEC's website at www.sec.gov . In addition to the risks described above and in Histogenics' annual report on Form 10-K and quarterly reports on Form 10-Q, current reports on Form 8-K and other filings with the SEC, other unknown or unpredictable factors also could affect Histogenics' results.

There can be no assurance that the actual results or developments anticipated by Histogenics will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Histogenics. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All written and verbal forward-looking statements attributable to Histogenics or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Histogenics cautions investors not to rely too heavily on the forward-looking statements Histogenics makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Histogenics undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.  

HISTOGENICS CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
 (in thousands, except share and per share data)
     
  March 31, 2015 December 31, 2014
  (unaudited)  
ASSETS    
Current assets:    
Cash and cash equivalents $53,181 $58,060
Prepaid expenses and other current assets 829 796
Total current assets 54,010 58,856
Property and equipment, net 5,422 4,878
Intangible asset, net 510 510
Noncurrent deferred tax assets, net 1,034 651
Restricted cash 604 604
Total assets $61,580 $65,499
     
LIABILITIES AND STOCKHOLDERS' EQUITY    
Current liabilities:    
Accounts payable $3,293 $4,886
Accrued expenses 1,896 1,683
Current portion of deferred rent 224 219
Current portion of deferred lease incentive 514 407
Current portion of equipment loan 538 405
Deferred tax liabilities, net 1,034 651
Total current liabilities 7,499 8,251
Deferred rent, long-term 445 379
Deferred lease incentive, long-term 1,213 1,318
Equipment loan, long-term 1,199 1,345
     
Total liabilities 10,356 11,293
     
Commitments and contingencies (Note 5)    
     
Stockholders' equity:    
Preferred stock, $0.01 par value; authorized shares - 10,000,000 at December 31, 2014 and March 31, 2015; none issued and outstanding at December 31, 2014 and March 31, 2015  --   -- 
Common stock, $0.01 par value; authorized shares - 100,000,000 at December 31, 2014 and March 31, 2015; 12,755,012 shares issued and outstanding at December 31, 2014 and 13,220,012 shares issued and outstanding at March 31, 2015 132 127
Additional paid-in capital  192,597 187,620
Accumulated deficit (141,505) (133,541)
Total stockholders' equity 51,224 54,206
Total liabilities and stockholders' equity $61,580 $65,499
 
HISTOGENICS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS 
(Unaudited)
(in thousands, except share and per share data)
     
  Three Months Ended March 31,
  2015 2014
     
Operating expenses:    
Research and development $5,764 $3,374
General and administrative 2,109 1,799
Total operating expenses 7,873 5,173
Loss from operations (7,873) (5,173)
     
Other income (expense):    
Interest expense, net (62)  -- 
Other income (expense), net (29) (2)
Change in fair value of warrant liability, other liability and net sales distribution payment liability  --  1,738
Total other income (expense), net (91) 1,736
Net loss $(7,964) $(3,437)
     
Loss attributable to common stockholders - basic and diluted $(7,964) $(3,437)
     
Loss per common share - basic and diluted: $(0.60) $(5.90)
     
Weighted-average shares used to compute earnings per common share - basic and diluted: 13,201,186 582,246

Investor Relations Tel: +1 (781) 547-7991

Scroll down for more posts ▼

Top 10 Most Recent News Articles

DarioHealth's New Research Tackles Healthcare Cost Estimation

Updated Category News Views 124

Unpacking Dario's Bold Surgical Strike at ISPOR Europe Alright, folks, DarioHealth is shaking up the stage with their new methodology that could very well carve a new path in how we size up digital healthcare savings. Presented at ISPOR Europe 2026, Dario's tactic bypasses the sluggish wait on medical claims data, instead offering an evidence-driven peek at potential...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 131

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading
Mercari and Suruga-ya Forge U.S. Venture for Culture

Updated Category News Views 189

Japanese Pop Culture Gears Up for US Market Surge Alright, folks, what we’ve got here is another bold move in the cross-border e-commerce game. Mercari and Suruga-ya are teaming up to establish a joint venture over in the U.S. The goal? To further capitalize on the growing appetite for Japanese entertainment and hobby goods among us all stateside. Now, it’s no secret...

Continue Reading
SwitchBot's Hub 4: A Step Toward a Connected Future

Updated Category News Views 67

Turning a House Into a Smart Home Haven Out of Tokyo and onto the world stage, SwitchBot's got something new cooking that might just shake up the smart home scene. They've launched the Hub 4, a gadget that's like the Swiss Army knife of home control. For those who like things simple, this is a one-hub-to-rule-them-all kind of deal. 101,000 Reasons to Notice Now, they...

Continue Reading
Sabre Unveils AI Travel Tech: A Bold New Frontier

Updated Category News Views 19

Sabre's Game-Changing AI Travel Integration I'm no stranger to bold moves in the travel industry, but what Sabre's rolling out tomorrow might just be the biggest leap we've seen in a while. They're unleashing what's called the first global travel plug-in within Grok Bot, marking a significant shake-up in the travel tech sphere. Too many tech upgrades in this business...

Continue Reading
XKIG Bolsters Northwest with Jensen's Acquisition

Updated Category News Views 29

Stepping Up the Game in the Pacific Northwest Well, here we see another classic example of a shrewd move in the infrastructure sector. XKIG, a name known to those who keep an eye on critical infrastructure services for utilities, has decided to widen its footprint with a strategic grab of Jensen's Tree Service, Inc. They’re setting up shop even deeper in the Pacific...

Continue Reading
Sharon Stuart's Quest for Her Hidden Origins

Updated Category News Views 55

Delving Into Identity: A Personal Odyssey In a world where everyone seems to be searching for something, Sharon Stuart's quest is etched with the raw need to uncover her real origins. Abandoned as a newborn in the gritty streets of Oakland, she grew up grappling with looming questions about what made her who she is. Her journey is captured in her memoir, "Existing Without...

Continue Reading
Graphic Packaging Shakes Up Leadership and Supply Chain

Updated Category News Views 81

New Leadership Takes the Helm at Graphic Packaging What do you do when you want to streamline an operation that spans continents? Well, if you're Graphic Packaging Holding Company (NYSE: GPK), you bring in fresh leadership to serenade the chaos into a well-oiled machine. Starting December 1, 2026, D. Keith Hamilton will be sinking his teeth into North America Mills &...

Continue Reading
IQSTEL's Nine-Month Revenue Hits $313M, Growth Impresses

Updated Category News Views 107

Pushing Through With Persistence Well, well, well, here we are, talking about IQSTEL Inc. (NASDAQ: IQST) slinging some serious numbers—not the kind you can ignore at your breakfast table. The company pulled in a whopping $313 million in revenue over the first nine months of 2026. That’s a bump up by 34.5% from last year’s $232.7 million. What’s behind the magic...

Continue Reading
Tenax Class Action: Investors Alley Fight for Redress

Updated Category News Views 33

Tenax Therapeutics in Hot Water Over Drug Trial Results Amidst the ever-unpredictable tides of the pharmaceutical industry, here comes a doozy – Tenax Therapeutics, Inc. is neck-deep in a shareholder lawsuit. If you tossed some money at NASDAQ:TENX anytime between November 13, 2023, and August 7, 2026, you might be feeling the sting of regret, and rightly so. What Went...

Continue Reading

Top 5 Most Recently Viewed Articles

Enhancing Enterprise Security Through Browser Integration

Updated Category News Views 280

Enhancing Enterprise Security Through Browser Integration Seraphic recently announced an exciting expansion of its collaboration with the CrowdStrike Falcon platform, a move poised to revolutionize browser-layer security. This integration provides users with an enhanced approach to managing digital threats, bringing powerful visibility and control to browser activities...

Continue Reading
Smirnoff ICE Unveils Exciting New Sunsurance Initiative

Updated Category News Views 433

Introducing Sunsurance from Smirnoff ICE Summer is just around the corner, and with it comes the excitement of sunny days, picnics, and outdoor gatherings. Smirnoff ICE is generating buzz with its latest initiative, Sunsurance, promising to elevate your summer experience. This innovative program is designed to ensure that regardless of what the weather brings, you can...

Continue Reading
First Watch Restaurant Group's Upcoming Conference Engagement

Updated Category News Views 175

First Watch Restaurant Group to Engage at Growth Frontiers Conference First Watch Restaurant Group, Inc. (Nasdaq: FWRG), considered a beacon in the Daytime Dining scene, is set to make its mark at the highly anticipated Piper Sandler’s Growth Frontiers Conference. This event will be held from September 9-11 and will feature a remarkable platform for discussion and...

Continue Reading
Detailed Insight on Rathbones Group Plc's Recent Disclosures

Updated Category News Views 111

Overview of Rathbones Group Plc's Key Disclosures Rathbones Group Plc has recently made significant public disclosures regarding its shareholding and investment positions in relation to De La Rue Plc. These disclosures are pivotal as they provide insights into the company’s financial dealings and interests in relevant securities, particularly those representing 1% or...

Continue Reading
Stride, Inc. Faces Class Action Lawsuit Over Alleged Fraud

Updated Category News Views 180

Class Action Lawsuit Against Stride, Inc. In recent developments, leading securities law firm Bleichmar Fonti & Auld LLP has initiated a class action lawsuit against Stride, Inc. (NYSE: LRN) for alleged securities fraud. This lawsuit follows significant stock price declines attributed to potential violations of federal securities laws. The Nature of the Allegations...

Continue Reading